In our weekly check, Travere Therapeutics, Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 9 pass, warnings: 1, red flags: 8.
Sector: Healthcare · Biotechnology
Next earnings report: 2026-10-29
PTCT · COGT · CRSP · ERAS · ORKA · MIRM
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks graded D or F lost a third of their value 2-3 times as often as those graded A or B.
Updated 2026-10-03